| May 31 |
Novartis reports positive Phase 3 data for remibrutinib for chronic hives
|
| May 31 |
Novartis' Oral Drug For Chronic Skin Disease Candidate Shows Efficacy, Long-term Safety
|
| May 31 |
Novartis Scemblix® Phase III data first to show superior efficacy with a favorable safety and tolerability profile vs. standard-of-care TKIs in adults with newly diagnosed CML
|
| May 31 |
Novartis reports Phase III data for trials of remibrutinib to treat CSU
|
| May 31 |
Novartis study points to larger role for targeted leukemia drug
|
| May 30 |
Novartis Phase III data confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria
|
| May 30 |
Novartis ending development of phase 3 KRAS lung cancer drug - report
|
| May 30 |
Why Is Lilly (LLY) Up 4.5% Since Last Earnings Report?
|
| May 28 |
Novartis reports Phase 3 results for IgA nephropathy treatment
|
| May 28 |
Roche’s Sabry retires; Duchenne drug fails confirmatory test
|
